Literature DB >> 8445062

An approach to the treatment of moderate to severe psoriasis with rotational therapy.

G D Weinstein1, G M White.   

Abstract

BACKGROUND: There are four standard approaches for treating moderate to severe psoriasis: UVB plus tar, PUVA, methotrexate, and etretinate. Although patients with psoriasis receive these therapies for many years, there is no commonly accepted approach for the initial and subsequent selection of the alternatives.
OBJECTIVE: Our purpose was to develop a theoretical and practical basis for using these treatments that will minimize the risks of their long-term toxicities and prolong their safe long-term use.
METHODS: A review of the published side effects of the treatments and cumulative clinical experience are used to develop an approach for the treatment of severe psoriasis.
RESULTS: It is proposed that patients receive each form of therapy for 1 to 2 years and then switch to the next form of treatment. By rotating each of the three or four treatments at these time intervals, it may well be 4 or 5 years before needing to return to the first therapy, thereby minimizing cumulative toxicity by long periods off each treatment.
CONCLUSION: Rotation of available therapies for moderate to severe psoriasis may minimize long-term toxicity and allow effective treatments to be maintained for many years.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445062     DOI: 10.1016/0190-9622(93)70067-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?

Authors:  B Lindelöf
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

4.  Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

Authors:  Tiffani Hamilton; Alan Menter; Ivor Caro; Peter Compton; Jeffrey Sobell; Kim A Papp
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice.

Authors:  Chong Won Choi; Bo Ri Kim; Jungyoon Ohn; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2017-02-03       Impact factor: 1.444

Review 6.  Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.

Authors:  Deepak M W Balak; Sascha Gerdes; Aurora Parodi; Laura Salgado-Boquete
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-11

7.  Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All?

Authors:  Bo Ri Kim; Jungyoon Ohn; Chong Won Choi; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.